NiedlFree Technologies has announced that Ozulin, an oral insulin spray to treat type 1 and 2 diabetes, will hit the Indian and global markets by 2025-26.
Insulin is a life-saving injectable medication used to manage blood sugar levels in individuals with diabetes. (Creative Commons)
For most type 1 diabetics around the world, their day begins with meticulously measuring and preparing the appropriate dose of insulin, ensuring that it aligns with their meal plan and activity level for the day.
Insulin is a life-saving medication used to manage blood sugar levels in individuals with diabetes. It is administered via injections, typically subcutaneously (under the skin), and helps regulate and control blood glucose (sugar) levels.
Each injection serves as a lifeline, allowing the user to regulate their blood sugar levels and maintain a sense of normalcy in life.
But now, there is some good news for insulin-injecting type 1 diabetics.
Hyderabad-based NiedlFree Technologies Private Limited has announced that Ozulin, an oral insulin spray to treat type 1 and 2 diabetes, will hit the Indian and global markets by 2025-26. NiedlFree Technologies was formed two years ago as an associate company of Transgene Biotek Limited.
This needle-free, oral spray — as a simple alternative to injectable insulin — to control and manage diabetes is a first-of-its-kind in the world. “NiedlFree will provide a huge relief to the diabetic population around the world once Ozulin hits the markets,” said Directors Dr K Koteswara Rao, Viswanath Toshniwal, and Dr Jeetendra Ambulge in a joint statement.
Dr Koteswara Rao, also the Managing Director of Transgene Bioteck, said that the team saw potential opportunities for their novel formulations in the animal care division as well, with the global pet care market for diabetes estimated to be around $2 billion (₹16,000 crore) in 2022.
“We are in dialogue with companies in the USA and Europe for a strategic alliance to introduce this novel Insulin product into the pet care markets during the fiscal year 2024-25, a prelude to its introduction into the human diabetic market around the world,” he said.
“This revolutionary technology was initiated by Transgene Bioteck nearly two decades ago but NiedlFree has now taken this project up, leading to its current exciting evolution,” he added.
Results of a recently-concluded study in dogs carried out by Palamur Biosciences provide ample proof of effectiveness of our oral Insulin, Dr Rao claimed.
The directors added that the total revenues from diabetes drugs around the world in 2022 was said to be $78 billion (₹6,24,000 crore — type 1 and type 2 combined).
Since insulin is the preferred drug of choice for most diabetics, nasal or oral insulin intake provides comfort as an effective alternative to all other diabetes drugs, Dr Rao claimed.
“We are establishing a facility in Hyderabad to produce this novel Insulin product and, currently, on a pilot project basis, we have got global patents for this novel oral insulin,” he further announced.
The company has invested ₹25 crore so far, as informed by the directors.
“With the success of this oral Insulin, we are poised to extend the transformation of several other injectable formulations across various medical segments, targeting specifically those conditions that are debilitating — Alzheimer’s, Parkinson’s, cancer requiring administration of medication through the IV route, osteoporosis, etc,” he added.
May 14, 2024
May 13, 2024
May 13, 2024
May 13, 2024
May 13, 2024
May 11, 2024
